

The Public Notice
Evidence Based Benefit Review Advisory Committee (EBBRAC)
Recommendations and New York State Department of Health's
Coverage Determinations

This public notice is being issued pursuant to Social Services Law section 365-d (7).

Recommendations and Determinations for EBBRAC Meeting Held: Thursday, December 15, 2016 from 10:00 am – 3:30 pm at the Empire State Plaza, Concourse Level in Meeting Room 1, Albany, NY.

Topics Reviewed:

- Implantable Infusion Pumps for non-cancer pain
- Lorcaserin (Belviq®)
- Digital Breast Tomosynthesis

Recommendations and Determinations by Topic

Implantable Infusion Pumps for non-cancer pain

Recommendation: EBBRAC (the Committee) recommended non-coverage of implantable infusion pumps for non-cancer pain.

Coverage Determination: The New York State (NYS) Department of Health (the Department) has determined not to expand Medicaid coverage of implantable infusion pumps to include non-cancer pain.

Analysis of Determination's Impact on NYS Medicaid's population and providers: The NYS Medicaid program continues to cover a variety of pain management interventions for non-cancer pain, including medications and physical therapy. This determination should have no impact on the NYS Medicaid population or providers.

Projected Fiscal Impact of Determination to NYS Medicaid Program: None



Lorcaserin (Belviq®)

Recommendation: The Committee recommended non-coverage of lorcaserin (Belviq®) for the pharmacologic management of weight.

Coverage Determination: The Department has determined not to expand Medicaid coverage to include lorcaserin (Belviq®) for the pharmacologic management of weight.

Analysis of Determination's Impact on NYS Medicaid's population and providers: The NYS Medicaid program continues to cover several interventions to assist in weight management, including primary care services and bariatric surgery.

Projected Fiscal Impact of Determination to NYS Medicaid Program: None



Digital Breast Tomosynthesis

Recommendation: The Committee recommended coverage of digital breast tomosynthesis (DBT) for the diagnosis and screening of breast cancer.

Coverage Determination: The Department has determined to expand NYS Medicaid coverage to include DBT for breast cancer screening mammography only. NYS Medicaid fee-for-service and Medicaid Managed Care will provide coverage for screening DBT beginning September 1, 2017 and November 1, 2017, respectively.

Analysis of Determination's Impact on NYS Medicaid's population and providers: Coverage of DBT offers an additional screening tool for NYS Medicaid providers and the NYS Medicaid population to assist in breast cancer diagnosis. The NYS Medicaid program continues to cover breast cancer screening and diagnostic technologies including digital mammography, ultrasound, and magnetic resonance imaging (MRI).

Projected Fiscal Impact of Determination to NYS Medicaid Program: The NYS Medicaid program paid \$3.2 million in total State share for digital breast tomosynthesis in calendar year 2018.